F5381
富马酸铁 (II)
≥95%
别名:
富马酸亚铁
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C4H2FeO4
化学文摘社编号:
分子量:
169.90
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
205-447-7
MDL number:
Assay:
≥95%
assay
≥95%
InChI key
PMVSDNDAUGGCCE-TYYBGVCCSA-L
InChI
1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;
SMILES string
O=C1O[Fe]OC(=O)\C=C\1
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 3
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Divya Yadava et al.
Journal of microencapsulation, 29(8), 729-738 (2012-08-10)
An extrusion-based encapsulation process has been developed for making salt grain-sized iron premix for salt fortification. The first step of extrusion agglomeration process has been studied and reported previously. The focus of this study is on the optimisation of the
Yao Olive Li et al.
Journal of microencapsulation, 28(7), 639-649 (2011-08-10)
A microencapsulation-based technology platform has been developed for salt double fortification with iron and iodine, aiming to address two globally prevalent micronutrient deficiencies simultaneously. Specifically, ferrous fumarate was microencapsulated into a form of salt grain-sized premix, and then added into
Pilar Garrido-Martín et al.
Interactive cardiovascular and thoracic surgery, 15(6), 1013-1018 (2012-09-04)
Anaemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. In our study we test the clinical effectiveness of intravenous and oral iron supplementation in correcting anaemia, and its
Yao Olive Li et al.
Food and nutrition bulletin, 30(4), 327-335 (2010-05-26)
Ferrous fumarate is useful in iron fortification because of its high bioavailability, mild taste, and relatively low cost. A ferrous fumarate premix for incorporation into salt has been developed by agglomerating ferrous fumarate with appropriate binder materials into salt-size particles
Min Lu et al.
American journal of hematology, 85(5), 315-319 (2010-03-05)
On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme injection, AMAG Pharmaceuticals), an iron-containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持